Emergent BioSolutions Selects Axiom Fusion eClinical Suite as Its Global eClinical Suite
Emergent BioSolutions Inc. (EBS)
Last emergent biosolutions inc. earnings: 4/30 04:08 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.emergentbiosolutions.com
Company Research
Source: GlobeNewswire
TORONTO, March 04, 2020 (GLOBE NEWSWIRE) -- Axiom Real-Time Metrics (“Axiom”), premier provider of unified eClinical solutions and services is pleased to announce its engagement with Emergent BioSolutions (NYSE: EBS), a global life sciences company whose mission is to protect and enhance life by providing specialty products and contract development and manufacturing services that address public health threats. Andrew Schachter, Founder & CEO of Axiom, shared, “Axiom is passionate about giving sponsors solutions that harness the power of their data to drive clinical research. We deliver technology and services to innovative life sciences organizations to provide them with the information that they need – in real-time – so that they are empowered with the robust and timely insights which are required for compliance, effective trial conduct, and successful drug development. We are very pleased to build this relationship with Emergent and potentially be a long-term partner in meetin
Show less
Read more
Impact Snapshot
Event Time:
EBS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EBS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EBS alerts
High impacting Emergent BioSolutions Inc. news events
Weekly update
A roundup of the hottest topics
EBS
News
- Emergent BioSolutions Inc (EBS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]Yahoo! Finance
- Mpox Vaccine Player Emergent BioSolutions Stock Jumps On Upbeat Annual Forecast, Expects Smaller Losses In 2024 [Yahoo! Finance]Yahoo! Finance
- Emergent BioSolutions Inc. (NYSE: EBS) had its price target raised by analysts at Benchmark Co. from $8.00 to $12.00. They now have a "buy" rating on the stock.MarketBeat
- Emergent BioSolutions (EBS) Q3 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa [Yahoo! Finance]Yahoo! Finance
EBS
Earnings
- 11/6/24 - Beat
EBS
Sec Filings
- 11/14/24 - Form 4
- 11/13/24 - Form 4
- 11/13/24 - Form 4
- EBS's page on the SEC website